Valeant to cut thousands of jobs after Bausch & Lomb buy
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals is making good on its promise to cut $800 million in costs following the Canadian specialty pharma companys's pending $8.7 billion acquisition of Bausch & Lomb and will cut 10% to 15% of its work force – a few thousand employees – in the process.